BioSpace News Archive

FSD Pharma Inc. is pleased to announce that it has entered into an at the market offering agreement with H.C. Wainwright & Co., LLC, pursuant to which the Company, at its discretion, may offer and sell, from time to time, through Wainwright as sales agent, Class B Subordinate Voting Shares in the capital of the Company having an aggregate offering price of up to US$11,154,232.

AstraZeneca’s TAGRISSO® with the addition of chemotherapy has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.

IGC Pharma, Inc. announced its financial results for the third fiscal quarter of 2024 ended December 31, 2023.

Iovance Biotherapeutics, Inc. announced that on February 15, 2024, the Company approved the grant of inducement stock options covering an aggregate of 40,450 shares of Iovance’s common stock to sixteen new non-executive employees.

The Melanoma Research Alliance, the largest non-profit funder of melanoma research worldwide, welcomes the U.S. Food and Drug Administration decision to approve Iovance Biotherapeutics’ AMTAGVI™ for the treatment of patients with advanced melanoma in the second line treatment setting.